FGF23 and chronic kidney disease: The same dilemma was observed in the ViRTUE-CKD trial, which demonstrated that the vitamin D receptor activator paricalcitol lowers albuminuria in chronic kidney disease patients, but at the same time increases markers of deregulated phosphate homeostasis (i.e., fibroblast growth factor 23) and vascular calcification propensity [45].